Safety profile of dual TIGIT and PD-L1 blockade with tiragolumab plus atezolizumab in solid tumors: a systematic review and meta-analysis of randomized controlled trials

Zaher Mutaz Ashour, Mus’ab Theeb Mustafa, Osama Wadah Rammaha, Abdallah Moh’d Said Hamdan, Yihea Mohammad Al-Mashaqbah, Abdallah Yaser Alasmar, Lou’y Ahmed Al-Rabaeh, Mohammad AlElaimat, Ayham Omar Khalifah, Omar Jamal Ramadan, Aws Khalid Abushanab, Abdulqadir J. Nashwan

Open source

DOI: 10.1080/14740338.2026.2704844
Published: 2026-08-12
Container: Expert Opinion on Drug Safety
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14740338.2026.2704844,
  title = {Safety profile of dual TIGIT and PD-L1 blockade with tiragolumab plus atezolizumab in solid tumors: a systematic review and meta-analysis of randomized controlled trials},
  author = {Zaher Mutaz Ashour and Mus’ab Theeb Mustafa and Osama Wadah Rammaha and Abdallah Moh’d Said Hamdan and Yihea Mohammad Al-Mashaqbah and Abdallah Yaser Alasmar and Lou’y Ahmed Al-Rabaeh and Mohammad AlElaimat and Ayham Omar Khalifah and Omar Jamal Ramadan and Aws Khalid Abushanab and Abdulqadir J. Nashwan},
  year = {2026},
  journal = {Expert Opinion on Drug Safety},
  doi = {10.1080/14740338.2026.2704844},
  url = {https://doi.org/10.1080/14740338.2026.2704844}
}

RIS

TY  - JOUR
TI  - Safety profile of dual TIGIT and PD-L1 blockade with tiragolumab plus atezolizumab in solid tumors: a systematic review and meta-analysis of randomized controlled trials
AU  - Zaher Mutaz Ashour
AU  - Mus’ab Theeb Mustafa
AU  - Osama Wadah Rammaha
AU  - Abdallah Moh’d Said Hamdan
AU  - Yihea Mohammad Al-Mashaqbah
AU  - Abdallah Yaser Alasmar
AU  - Lou’y Ahmed Al-Rabaeh
AU  - Mohammad AlElaimat
AU  - Ayham Omar Khalifah
AU  - Omar Jamal Ramadan
AU  - Aws Khalid Abushanab
AU  - Abdulqadir J. Nashwan
PY  - 2026
JO  - Expert Opinion on Drug Safety
DO  - 10.1080/14740338.2026.2704844
UR  - https://doi.org/10.1080/14740338.2026.2704844
ER  -

APA

Ashour, Z. M., Mustafa, M. T., Rammaha, O. W., Hamdan, A. M. S., Al-Mashaqbah, Y. M., Alasmar, A. Y., Al-Rabaeh, L. A., AlElaimat, M., Khalifah, A. O., Ramadan, O. J., Abushanab, A. K., & Nashwan, A. J. (2026). Safety profile of dual TIGIT and PD-L1 blockade with tiragolumab plus atezolizumab in solid tumors: a systematic review and meta-analysis of randomized controlled trials. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2026.2704844

Source records

crossref · retrieved 2026-09-26T14:12:57.741Z